Additional file 6 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)
Additional file 6: Categorization of identified PGx associations denoting altered metabolisation efficiency of CYP2C9, CYP2C19 and CYP2D6, on 501 patients, denoted as minimum (homozygotic, no polymorphism); intermediate (heterozygotic polymorphism) and enhanced (homozygotic polymorphism), including...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Dataset |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | E. Bothos E. Ntoumou K. Kelaidoni D. Roukas N. Drakoulis M. Papasavva F. A. Karakostis P. Moulos Karakostis, K. |
| description | Additional file 6: Categorization of identified PGx associations denoting altered metabolisation efficiency of CYP2C9, CYP2C19 and CYP2D6, on 501 patients, denoted as minimum (homozygotic, no polymorphism); intermediate (heterozygotic polymorphism) and enhanced (homozygotic polymorphism), including the Age and the sex factors. |
| doi_str_mv | 10.6084/m9.figshare.14429410 |
| format | Dataset |
| fullrecord | <record><control><sourceid>datacite_PQ8</sourceid><recordid>TN_cdi_datacite_primary_10_6084_m9_figshare_14429410</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_6084_m9_figshare_14429410</sourcerecordid><originalsourceid>FETCH-LOGICAL-d910-728b7c5652ef2f8caf60107ad825fa640a57102f69e7a33d2a81fe65c2e1a94a3</originalsourceid><addsrcrecordid>eNpVkLtOAzEQRbehQIE_oJgSJBJs75suinhJERSkXw32eGNpba9sJ1K-kZ9il0dBNZqrozOjm2VXnK0q1hR3tl1p08c9BlrxohBtwdl59rlWyiTjHQ6gzUBQgdewGYwzcorGCbcofU_OWyMjGAcoZ_4eFEXTu1vAGClGSy4BOgXGjgPNG87YbENw_kj_ZJSMhBHdlMbDOPqQjOtBhUMPkQb6vgDaB1AmEk7-2ZP2BHISh-kxR-HoDxHiKSaycL15fb-5yM40DpEuf-ci2z0-7DbPy-3b08tmvV2qlrNlLZqPWpZVKUgL3UjUFeOsRtWIUmNVMCxrzoSuWqoxz5XAhmuqSimIY1tgvsiKH63ChNIk6sZgLIZTx1k3V93ZtvuruvurOv8C79yAGw</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>dataset</recordtype></control><display><type>dataset</type><title>Additional file 6 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)</title><source>DataCite</source><creator>E. Bothos ; E. Ntoumou ; K. Kelaidoni ; D. Roukas ; N. Drakoulis ; M. Papasavva ; F. A. Karakostis ; P. Moulos ; Karakostis, K.</creator><creatorcontrib>E. Bothos ; E. Ntoumou ; K. Kelaidoni ; D. Roukas ; N. Drakoulis ; M. Papasavva ; F. A. Karakostis ; P. Moulos ; Karakostis, K.</creatorcontrib><description>Additional file 6: Categorization of identified PGx associations denoting altered metabolisation efficiency of CYP2C9, CYP2C19 and CYP2D6, on 501 patients, denoted as minimum (homozygotic, no polymorphism); intermediate (heterozygotic polymorphism) and enhanced (homozygotic polymorphism), including the Age and the sex factors.</description><identifier>DOI: 10.6084/m9.figshare.14429410</identifier><language>eng</language><publisher>figshare</publisher><subject>Biotechnology ; Cancer ; Cell Biology ; Computational Biology ; Environmental Sciences not elsewhere classified ; FOS: Biological sciences ; FOS: Earth and related environmental sciences ; FOS: Health sciences ; Genetics ; Hematology ; Infectious Diseases ; Medicine ; Molecular Biology ; Neuroscience ; Pharmacology ; Physiology ; Virology</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0003-1122-7860</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776,1888</link.rule.ids><linktorsrc>$$Uhttps://commons.datacite.org/doi.org/10.6084/m9.figshare.14429410$$EView_record_in_DataCite.org$$FView_record_in_$$GDataCite.org$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>E. Bothos</creatorcontrib><creatorcontrib>E. Ntoumou</creatorcontrib><creatorcontrib>K. Kelaidoni</creatorcontrib><creatorcontrib>D. Roukas</creatorcontrib><creatorcontrib>N. Drakoulis</creatorcontrib><creatorcontrib>M. Papasavva</creatorcontrib><creatorcontrib>F. A. Karakostis</creatorcontrib><creatorcontrib>P. Moulos</creatorcontrib><creatorcontrib>Karakostis, K.</creatorcontrib><title>Additional file 6 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)</title><description>Additional file 6: Categorization of identified PGx associations denoting altered metabolisation efficiency of CYP2C9, CYP2C19 and CYP2D6, on 501 patients, denoted as minimum (homozygotic, no polymorphism); intermediate (heterozygotic polymorphism) and enhanced (homozygotic polymorphism), including the Age and the sex factors.</description><subject>Biotechnology</subject><subject>Cancer</subject><subject>Cell Biology</subject><subject>Computational Biology</subject><subject>Environmental Sciences not elsewhere classified</subject><subject>FOS: Biological sciences</subject><subject>FOS: Earth and related environmental sciences</subject><subject>FOS: Health sciences</subject><subject>Genetics</subject><subject>Hematology</subject><subject>Infectious Diseases</subject><subject>Medicine</subject><subject>Molecular Biology</subject><subject>Neuroscience</subject><subject>Pharmacology</subject><subject>Physiology</subject><subject>Virology</subject><fulltext>true</fulltext><rsrctype>dataset</rsrctype><creationdate>2021</creationdate><recordtype>dataset</recordtype><sourceid>PQ8</sourceid><recordid>eNpVkLtOAzEQRbehQIE_oJgSJBJs75suinhJERSkXw32eGNpba9sJ1K-kZ9il0dBNZqrozOjm2VXnK0q1hR3tl1p08c9BlrxohBtwdl59rlWyiTjHQ6gzUBQgdewGYwzcorGCbcofU_OWyMjGAcoZ_4eFEXTu1vAGClGSy4BOgXGjgPNG87YbENw_kj_ZJSMhBHdlMbDOPqQjOtBhUMPkQb6vgDaB1AmEk7-2ZP2BHISh-kxR-HoDxHiKSaycL15fb-5yM40DpEuf-ci2z0-7DbPy-3b08tmvV2qlrNlLZqPWpZVKUgL3UjUFeOsRtWIUmNVMCxrzoSuWqoxz5XAhmuqSimIY1tgvsiKH63ChNIk6sZgLIZTx1k3V93ZtvuruvurOv8C79yAGw</recordid><startdate>20210416</startdate><enddate>20210416</enddate><creator>E. Bothos</creator><creator>E. Ntoumou</creator><creator>K. Kelaidoni</creator><creator>D. Roukas</creator><creator>N. Drakoulis</creator><creator>M. Papasavva</creator><creator>F. A. Karakostis</creator><creator>P. Moulos</creator><creator>Karakostis, K.</creator><general>figshare</general><scope>DYCCY</scope><scope>PQ8</scope><orcidid>https://orcid.org/0000-0003-1122-7860</orcidid></search><sort><creationdate>20210416</creationdate><title>Additional file 6 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)</title><author>E. Bothos ; E. Ntoumou ; K. Kelaidoni ; D. Roukas ; N. Drakoulis ; M. Papasavva ; F. A. Karakostis ; P. Moulos ; Karakostis, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-d910-728b7c5652ef2f8caf60107ad825fa640a57102f69e7a33d2a81fe65c2e1a94a3</frbrgroupid><rsrctype>datasets</rsrctype><prefilter>datasets</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Biotechnology</topic><topic>Cancer</topic><topic>Cell Biology</topic><topic>Computational Biology</topic><topic>Environmental Sciences not elsewhere classified</topic><topic>FOS: Biological sciences</topic><topic>FOS: Earth and related environmental sciences</topic><topic>FOS: Health sciences</topic><topic>Genetics</topic><topic>Hematology</topic><topic>Infectious Diseases</topic><topic>Medicine</topic><topic>Molecular Biology</topic><topic>Neuroscience</topic><topic>Pharmacology</topic><topic>Physiology</topic><topic>Virology</topic><toplevel>online_resources</toplevel><creatorcontrib>E. Bothos</creatorcontrib><creatorcontrib>E. Ntoumou</creatorcontrib><creatorcontrib>K. Kelaidoni</creatorcontrib><creatorcontrib>D. Roukas</creatorcontrib><creatorcontrib>N. Drakoulis</creatorcontrib><creatorcontrib>M. Papasavva</creatorcontrib><creatorcontrib>F. A. Karakostis</creatorcontrib><creatorcontrib>P. Moulos</creatorcontrib><creatorcontrib>Karakostis, K.</creatorcontrib><collection>DataCite (Open Access)</collection><collection>DataCite</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>E. Bothos</au><au>E. Ntoumou</au><au>K. Kelaidoni</au><au>D. Roukas</au><au>N. Drakoulis</au><au>M. Papasavva</au><au>F. A. Karakostis</au><au>P. Moulos</au><au>Karakostis, K.</au><format>book</format><genre>unknown</genre><ristype>DATA</ristype><title>Additional file 6 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS)</title><date>2021-04-16</date><risdate>2021</risdate><abstract>Additional file 6: Categorization of identified PGx associations denoting altered metabolisation efficiency of CYP2C9, CYP2C19 and CYP2D6, on 501 patients, denoted as minimum (homozygotic, no polymorphism); intermediate (heterozygotic polymorphism) and enhanced (homozygotic polymorphism), including the Age and the sex factors.</abstract><pub>figshare</pub><doi>10.6084/m9.figshare.14429410</doi><orcidid>https://orcid.org/0000-0003-1122-7860</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | DOI: 10.6084/m9.figshare.14429410 |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_datacite_primary_10_6084_m9_figshare_14429410 |
| source | DataCite |
| subjects | Biotechnology Cancer Cell Biology Computational Biology Environmental Sciences not elsewhere classified FOS: Biological sciences FOS: Earth and related environmental sciences FOS: Health sciences Genetics Hematology Infectious Diseases Medicine Molecular Biology Neuroscience Pharmacology Physiology Virology |
| title | Additional file 6 of Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T06%3A05%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-datacite_PQ8&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.au=E.%20Bothos&rft.date=2021-04-16&rft_id=info:doi/10.6084/m9.figshare.14429410&rft_dat=%3Cdatacite_PQ8%3E10_6084_m9_figshare_14429410%3C/datacite_PQ8%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |